In fact, disrupted SREBP-1 levels, increased HMG-CoA expression and decreased PON 1 activity have evidenced in NAFLD promoting a dysregulation of lipid metabolism [28,38,40,42]. The gene discussed is PON1; the disease is metabolic dysfunction-associated steatotic liver disease.